Robert Pilarski, is Clinical Affairs Director at Ambry Genetics working on aligning payer policies and national genetic testing guidelines. Prior to this he was a licensed and board certified genetic counselor and Professor of Clinical Internal Medicine at the Wexner Medical Center and James Comprehensive Cancer Center at The Ohio State University. Mr. Pilarski’s clinical responsibilities included counseling patients and families with a variety of hereditary cancer syndromes. In addition he researched on clinical aspects of Cowden syndrome and the PTEN Hamartoma Tumor syndrome (PHTS) and he was the study coordinator and co-investigator for the OSU Breast Cancer Tissue Bank and a study on the Genetics of Uveal Melanoma, which helped identify BAP1 as a tumor predisposition gene. He has over 90 publications in medical and scientific journals. He has presented regularly at national and regional conferences, and has served as an ad hoc review for numerous medical and genetics journals. Mr. Pilarski was a past board member of the National Society of Genetic Counselors, and co-founder and past president of its Cancer Genetics Special Interest Group. Until joining Ambry Genetics he was the vice-chair of the National Comprehensive Cancer Network’s guidelines panel on Genetic/Familial High Risk Assessment: Breast and Ovarian Cancers, which set testing and management guidelines for individuals at risk for hereditary breast and ovarian cancers.